TB-500 is a synthetic analog of the naturally occurring peptide Thymosin Beta-4 (Tβ4), a ubiquitous 43-amino acid protein found in virtually every cell of the body. As a research compound, TB-500 has attracted considerable scientific attention due to its ability to bind G-actin (monomeric actin) and modulate actin dynamics — a process central to cell migration, tissue organization, and wound response signaling. Preclinical studies have explored TB-500 across a wide range of tissue models, making it one of the more broadly investigated peptides in contemporary laboratory research.
Understanding the biology of TB-500 begins with its primary molecular target: the LKKTET actin-binding domain. This core sequence mediates interactions between Tβ4 and cytoskeletal proteins, and it is this same domain that researchers believe underlies the peptide’s observed effects in preclinical models of tissue remodeling, angiogenesis, and cellular migration. The following guide examines the mechanisms, receptor biology, and published preclinical findings associated with TB-500 research as of 2026.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. TB-500 is a research compound intended strictly for in vitro and preclinical laboratory use. It is not intended for human or animal administration.
TB-500 - 5MG — Research-Grade Reference Material TB-500 - 5MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
KPV - 10MG
$75.00$56.25 with 1st order
GLOW (GHK-CU, BPC-157 & TB-500) 70MG
$95.00$71.25 with 1st order
KLOW (GHK-CU, BPC-157, TB-500 & KPV) 80MG
$105.00$78.75 with 1st order
Selank (10MG) & Semax (10MG) – 20MG
$80.00$60.00 with 1st order
Frequently Asked Questions
What is TB-500?
TB-500 is a synthetic peptide derived from the active domain of Thymosin Beta-4 (Tβ4). It is used as a research compound in laboratory settings to study actin-binding biology, cell migration, and tissue remodeling mechanisms in preclinical models.
How does TB-500 work at the molecular level?
TB-500 contains the LKKTET actin-binding sequence, which allows it to sequester G-actin (globular, monomeric actin). This interaction modulates actin polymerization dynamics, influencing cytoskeletal organization, cell motility, and migration-related signaling pathways.
What tissues has TB-500 been studied in preclinically?
Preclinical research has examined TB-500 in cardiac tissue, skeletal muscle, connective tissue, skin, corneal models, and vascular biology. Studies have explored its effects on angiogenesis, cell migration, and extracellular matrix remodeling in these tissue contexts.
Is TB-500 the same as Thymosin Beta-4?
TB-500 is not identical to full-length Thymosin Beta-4. It is a synthetic peptide corresponding to the core actin-binding fragment of Tβ4 (typically the Ac-LKKTETQ sequence). While it shares key biological activity domains, the two compounds are distinct molecules with different molecular weights and structures.
What is the role of actin dynamics in TB-500 research?
Actin dynamics — the regulated cycling between G-actin (monomeric) and F-actin (filamentous) forms — are fundamental to cell shape, division, and migration. TB-500’s ability to sequester G-actin makes it a valuable research tool for studying how actin-binding peptides influence these fundamental biological processes.
Has TB-500 been studied alongside BPC-157?
Yes. TB-500 and BPC-157 are frequently examined together in preclinical research because they appear to act on complementary pathways related to tissue biology and cellular repair signaling. Several published preclinical studies have explored their combined effects in regenerative biology models.
Where can researchers source TB-500 for laboratory use?
Researchers can source TB-500 for laboratory purposes from qualified research peptide suppliers. It is available in lyophilized powder and nasal spray formulations for research use only.
Thymosin Beta-4 Biology: The Natural Foundation of TB-500 Research
To understand TB-500 as a research molecule, it is first necessary to appreciate the broader biology of Thymosin Beta-4. Tβ4 is one of the most abundant intracellular peptides in mammalian cells and is encoded by the TMSB4X gene. It is expressed in virtually all cell types, with particularly high concentrations observed in platelets, neutrophils, and macrophages — all of which are central to tissue injury response cascades.
TB-500 - 5MG — Research-Grade Reference Material TB-500 - 5MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
KPV - 10MG
$75.00$56.25 with 1st order
GLOW (GHK-CU, BPC-157 & TB-500) 70MG
$95.00$71.25 with 1st order
KLOW (GHK-CU, BPC-157, TB-500 & KPV) 80MG
$105.00$78.75 with 1st order
Selank (10MG) & Semax (10MG) – 20MG
$80.00$60.00 with 1st order
The primary known function of full-length Tβ4 is to bind G-actin in a 1:1 stoichiometric ratio. At physiological concentrations, Tβ4 sequesters a substantial fraction of the total cellular G-actin pool, acting as a critical buffer that modulates the availability of free actin monomers for polymerization into F-actin filaments. This sequestration activity directly influences the cell’s cytoskeletal architecture and, by extension, its capacity for migration, division, and morphological adaptation.
Beyond cytoskeletal modulation, published research has identified Tβ4’s involvement in several additional signaling pathways, including integrin-linked kinase (ILK) activation, which connects extracellular matrix signals to intracellular responses. TB-500, as the synthetic active-domain fragment, is studied as a tool to probe these same pathways with a molecularly defined and reproducible reagent.
Molecular Mechanism: Actin Sequestration and Cytoskeletal Signaling
The LKKTET Actin-Binding Domain
The functional core of TB-500 is its LKKTET motif — a short peptide sequence that forms a direct interaction with the ATP-binding cleft of G-actin. Structural studies using X-ray crystallography and NMR spectroscopy have mapped this interaction in considerable detail, revealing that the leucine and lysine residues of the LKKTET sequence make critical hydrophobic and electrostatic contacts with actin. This binding prevents G-actin from incorporating into growing F-actin filaments, effectively dampening local polymerization at sites where TB-500 is present.
From a research standpoint, this mechanism has several interesting downstream implications. Cells exposed to TB-500 in vitro have been observed to exhibit altered lamellipodia formation — the thin, sheet-like projections at the leading edge of migrating cells. Lamellipodia are actin-rich structures whose dynamics are tightly coupled to directional cell movement, making TB-500 a useful experimental tool for studying migration biology in wound-response and angiogenesis models.
Integrin-Linked Kinase Activation
Research has also implicated Tβ4 — and by extension TB-500 — in the activation of integrin-linked kinase (ILK), a multifunctional intracellular scaffold protein that transduces signals from integrins (cell-surface matrix receptors) to downstream effectors including Akt and GSK-3β. ILK activation has been linked in the literature to cell survival signaling, cytoskeletal organization, and the modulation of inflammatory mediators. Studies examining Tβ4/TB-500 in cardiac tissue models have specifically highlighted ILK-dependent signaling as a potential mechanism underlying observed effects on cardiomyocyte biology.
Preclinical Research Findings: Key Study Areas
Cardiac Tissue Biology
Some of the most extensively published preclinical work on Thymosin Beta-4 and its analogs has been conducted in cardiac tissue models. A series of studies published in Nature and related high-impact journals in the mid-2000s through 2010s examined Tβ4’s effects in rodent models of cardiac ischemia. These investigations observed that Tβ4 administration was associated with increased cardiomyocyte survival signals and enhanced mobilization of epicardial progenitor cells — a finding that prompted considerable interest in the peptide’s potential relevance to cardiovascular biology research.
A particularly notable preclinical finding involved the reactivation of quiescent epicardial cells in a murine infarction model, where Tβ4 appeared to restore a degree of embryonic-like epicardial activity. Researchers noted increased expression of Wilms’ Tumor 1 (WT1) — a transcription factor associated with epicardial progenitor cell identity — following Tβ4 exposure. While these findings remain firmly in the preclinical domain, they have established cardiac biology as one of the most active areas of Tβ4/TB-500 research interest.
Corneal and Ocular Tissue Models
TB-500 and Tβ4 have been studied in multiple corneal wound-healing models. Research examining corneal epithelial cell migration in vitro found that Tβ4 significantly accelerated scratch-wound closure in cell culture assays, an effect attributed to its enhancement of lamellipodia formation and directional migration through actin remodeling. These findings have made ocular biology one of the more active research contexts for TB-500-related peptide studies, and preclinical data in this area are among the most reproducible reported in the literature.
Vascular Biology and Angiogenesis
TB-500 research has explored its role in endothelial cell biology and angiogenesis — the formation of new blood vessels from existing vasculature. Preclinical studies in endothelial cell culture models demonstrated that Tβ4 promoted tube formation in Matrigel assays and increased endothelial cell migration, both hallmarks of pro-angiogenic activity. The mechanism proposed by researchers involves Tβ4-mediated ILK activation and subsequent downstream effects on vascular endothelial growth factor (VEGF) signaling cascades.
In rodent skin models, Tβ4 was associated with increased neovascularization at wound sites, suggesting that actin-binding peptides may play a role in the vascular remodeling phase of tissue repair. These findings are consistent with the peptide’s documented effects on endothelial cell cytoskeletal organization.
Skeletal Muscle and Connective Tissue Models
A growing body of preclinical literature has examined TB-500 in the context of skeletal muscle biology. Studies in rodent muscle injury models have reported accelerated regeneration of muscle fibers and increased satellite cell (muscle stem cell) activity following Tβ4 administration. Satellite cells rely on actin cytoskeletal remodeling for both activation from quiescence and subsequent migration to injury sites, making TB-500’s actin-binding properties mechanistically relevant to this research context.
Research into connective tissue models — including tendon and ligament explants — has similarly explored how TB-500 influences fibroblast migration and collagen synthesis, both key parameters in extracellular matrix remodeling studies. As detailed in the comprehensive BPC-157 research guide, BPC-157 operates through complementary mechanisms (particularly involving nitric oxide and growth factor signaling), which is why these two peptides are frequently studied in combination in connective tissue research models.
TB-500 and BPC-157: Complementary Research Pathways
A significant and growing area of research interest involves the combined study of TB-500 and BPC-157. These two peptides are mechanistically distinct but functionally complementary. BPC-157 primarily operates through modulation of nitric oxide signaling and growth factor receptor pathways (including VEGF-R2 and PDGF-R), while TB-500 acts upstream at the level of actin cytoskeletal organization. In preclinical models where both agents have been studied together, researchers have observed more pronounced effects on cellular migration and tissue organization than with either peptide alone — a pattern consistent with their different but synergistic mechanisms.
The GLOW peptide stack research guide examines this synergy in detail within the context of a multi-peptide research formulation combining GHK-Cu, BPC-157, TB-500, and KPV. For researchers interested in tissue biology applications, understanding how these components interact at the mechanistic level is essential for designing well-controlled preclinical experiments.
TB-500 10MG Nasal Spray — for laboratory research use →
Anti-Inflammatory Signaling Pathways in TB-500 Research
Beyond its cytoskeletal role, published literature has explored Tβ4’s interaction with inflammatory signaling cascades. Several in vitro studies have examined Tβ4’s ability to modulate NF-κB pathway activity — a master regulator of inflammatory gene transcription. In macrophage culture models, Tβ4 was associated with downregulation of pro-inflammatory cytokine expression, including TNF-α and IL-1β, suggesting that actin-binding peptides may influence immune cell phenotype through mechanisms that extend beyond simple cytoskeletal effects.
Research has also examined Tβ4’s relationship with oxidative stress markers in tissue culture models. In cardiac and hepatic cell lines, Tβ4 exposure was associated with reduced markers of oxidative injury, possibly through ILK-mediated Akt activation, which is known to upregulate antioxidant enzyme expression. This intersection of cytoskeletal biology and oxidative signaling represents an active area of ongoing preclinical inquiry.
Researchers studying immune-modulatory peptides may also find value in reviewing the GHK-Cu research overview, which covers another well-studied peptide with both tissue remodeling and inflammation-related research findings in preclinical models.
Research Formulations and Laboratory Considerations
Lyophilized Powder vs. Nasal Spray Formulations
For laboratory research purposes, TB-500 is available in two primary formats: lyophilized powder (for reconstitution with bacteriostatic water) and pre-formulated nasal spray preparations. The lyophilized format offers researchers flexibility in working concentration and is typically preferred for in vitro cell-based assays where precise concentration control is important. As covered in the bacteriostatic water quality guide, the choice of reconstitution vehicle can materially affect peptide stability and should be carefully considered in experimental design.
Nasal spray formulations of TB-500 are available for research contexts where transmucosal delivery mechanisms are being studied. The GLOW nasal spray formulation, which includes TB-500 alongside BPC-157, GHK-Cu, and KPV, is one example of a multi-peptide format available for preclinical investigation.
Storage and Stability Considerations
TB-500 in lyophilized form is generally stable when stored at -20°C, protected from light and moisture. Following reconstitution, research protocols typically specify storage at 4°C for short-term use, with freeze-thaw cycles minimized to preserve peptide integrity. Researchers should consult current literature for specific stability data relevant to their experimental conditions, as degradation kinetics can vary depending on buffer composition, concentration, and storage conditions.
BPC-157 10MG Nasal Spray — for laboratory research use →
GLOW (GHK-Cu, BPC-157, TB-500) 70MG Nasal Spray — for laboratory research use →
BPC-157 & TB-500 (Wolverine 20MG) Nasal Spray — for laboratory research use →
Where These Fit in Your Research Library
Researchers building a comprehensive peptide research library focused on tissue biology and regenerative signaling will find TB-500 an important reference compound to study alongside complementary peptides. Related research products available for laboratory investigation include:
- BPC-157 10MG Nasal Spray — studies cytoskeletal and nitric oxide-mediated tissue signaling pathways
- GHK-Cu 100MG Nasal Spray — copper-binding peptide with extracellular matrix and collagen biology applications
- GLOW 70MG Nasal Spray — multi-peptide stack formulation for combined tissue biology research
For the full catalog of research peptides, visit the SourcePeptides research compound catalog.
Final Takeaway: TB-500 as a Research Tool in 2026
TB-500 represents one of the most mechanistically well-characterized synthetic peptides available for preclinical research. Its role as a G-actin sequestering agent, combined with downstream effects on ILK signaling, inflammatory pathway modulation, and angiogenic biology, makes it a highly versatile tool for researchers studying fundamental questions in cell migration, tissue organization, and vascular biology.
The breadth of preclinical study contexts — from cardiac tissue and corneal models to skeletal muscle and connective tissue biology — reflects the peptide’s involvement in biological processes that are conserved across tissue types. As laboratory research techniques continue to advance, TB-500 is likely to remain a foundational reference compound for scientists investigating actin-binding peptide biology, cytoskeletal pharmacology, and tissue remodeling mechanisms. All research applications should be conducted in accordance with institutional guidelines and applicable regulations governing the use of research compounds in vitro.
Sources & Further Reading
- Bock-Marquette I et al. — “Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair” — Nature (2004)
- Smart N et al. — “Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization” — Nature (2007)
- Sosne G et al. — “Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury” — Experimental Eye Research (2002)
- Goldstein AL et al. — “Thymosin β4: actin-sequestering protein moonlights to repair injured tissues” — Trends in Molecular Medicine (2005)
- PubMed Search — Thymosin Beta-4 Preclinical Tissue Remodeling Research
